cyclin E1-directed MGD — IND submission
H2 2026
Monte Rosa expects to submit an IND application for its CCNE1 MGD program in H2 2026.Source filing
GLUE biotech catalysts & pipeline
MONTE ROSA THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
MRT-55811 — IND submission
H2 2026
Preclinical data presented at AACR highlight a novel cyclin E1-directed MGD with superior selectivity and reduced off-target activity compared to CDK2 inhibitors; IND submission anticipated in H2 2026Source filing
second-generation NEK7-directed MGD — IND submission
H2 2026
Submit an IND application for a second-generation NEK7-directed MGD in H2 2026.Source filing
MRT-2359 — Interim data
Late 2026
We will update data from the initial Phase 1/2 arm exploring MRT-2359 in advanced CRPC by the end of the year.Source filing
cyclin E1-directed MGD — IND submission
2027
Submit an IND application for a cyclin E1-directed MGD in 2027.Source filing
MRT-8102 — Initial data
H2 2027
Initial data are expected in H2 2027.Source filing